Evaluating inflammatory biomarkers as predictors of outcomes and immune-related adverse events (irAE) in the Big Ten Cancer Research Consortium (BTCRC) LUN16-081 phase II clinical trial.

Authors: Greg Andrew Durm, Sandra K. Althouse, Hirva Mamdani, Tushar Sardesai, Shadia Ibrahim Jalal, Nasser H. Hanna

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20087

Source: Full article


Abstract

e20087